Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NORLUTATE.
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining. Ferrous fumarate is an iron supplement for replacement of menstrual iron loss.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
One tablet (norethindrone 1 mg, ethinyl estradiol 10 mcg, and ferrous fumarate 75 mg) orally once daily at the same time each day for 28 consecutive days, starting on day 1 of menstrual cycle.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Norethindrone: 5-8 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal). Clinical context: dosing interval is 24 hours based on ethinyl estradiol half-life.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal via enterohepatic recirculation. Ferrous fumarate: iron is absorbed and incorporated; excess excreted in feces as unabsorbed.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin